EP Global Communications Inc fka EPGL

[jhnvtjll]

The Wall Street Journal writer who mentioned $InWith Corp, was also told that the revolution in new body technologies is starting RIGHT NOW, not 5 or 10 years. RIGHT NOW is when inventors and investors in this revolution are taking their places. "Common place" is far TOO LATE! InWith Corporation patented technologies were born in labs of multi-billion dollar companies and the integration of our platform is now happening in the labs of other industry leaders. In a joint statement, EPGL announces that it has received its third consecutive US Patent allowance in the field of ophthalmic technologies while start-up partner InWith Corp. announces it will make a bid to buyout EPGL. For EPGL, the allowed US Patent titled "Piezoelectric Sensor for Vision Correction" (U.S. 14/622,814), protects the sensing of the vibration of the ciliary muscle within the human eye, to trigger a self-focus mechanism within a soft contact lenses. EPGL's IP counsel was recently notified of the Allowance by the United States Patent and Trademark Office. InWith Corp., a start-up company with plans to make new "body technologies" from wearable devices to implantable devices tied to a mobile wireless network, announced that it is seeking as much as $500 million in private funding. InWith Corp. is a private company with 100 million authorized shares. InWith Corp. and EPGL previously announced a partnership to build EPGL's patented ophthalmic technologies. Several EPGL shareholders have requested and will receive a gift of Inwith Corp. equity. As a result, InWith Corp. will have private shareholders from all over the world. The Company has announced that Dr. Scott Peterson will be its Vice President. Dr. Peterson has been in practice for over 33 years and specializes in Glaucoma treatment and contact lenses. The management team of InWith Corp. will be fully announced by end of February 2017. InWith Corp. will make a bid to buyout EP Global Communications, Inc. (EPGL) if EPGL shareholders allow the full offer to be presented by InWith Corp. via a Proxy Vote. The offer will involve a choice for EPGL's retail shareholders to be bought out in a cash price of up to 9.8 cents per share, or to receive approximately 125% of their current EPGL equity by percentage (total along with gifted shares) converted to InWith Corp. equity. The choice would be offered as "one or the other" to EPGL shareholders and they could make their choice individually from other shareholders. In any event, EPGL shareholders who formally requested the InWith Corp. gift equity offer, will receive that gift equity regardless if a full buyout is finalized. EPGL will put the InWith Corp. detailed proposal before its shareholders in a Proxy Vote. The Company notes that other entities who hold first rights to purchase EPGL technologies, will continue to enjoy those rights through to the building of the products, regardless of any completed buyout. EP Global Communications, Inc. (OTC: EPGL) In a first for EPGL since acquiring 100% of its ophthalmic IP portfolio, one of the world's leading multi-billion-dollar public companies, in a brand-new relationship for EPGL, has made EPGL technology and its patented Elastic Circuit technology as the choice for a closely guarded and proprietary development of a new contact lens prototype to undergo FDA testing as early as next year. This goes beyond a right of first negotiation to now having EPGL technology at the center of a commercial project that addresses a multi-billion-dollar market in the field. "We are on target with our strategy and the proof is that major companies are now choosing EPGL tech for actual market commercialization, not just first rights. Just as the number of our patents has grown, the number of corporate suitors for our technology will grow exponentially, I predict. Smart investors should take positions now if they believe we have growth potential for the next phase of EPGL and InWith, which starts today," said Michael Hayes. "As we promised, our patents are getting granted and becoming more and more valuable to other major entities as they begin to pursue projects for the next generation of vision care and augmentation. The next phase has started and savvy investors can participate." In addition to the brand-new developments announced here today, EPGL and InWith (www.inwithcorp.com) plan to announce major venture capital partners between now and the holiday season. As a new start-up, InWith will license EPGL technology and is aggressively pursuing the InLens / Omega autofocus projects announced earlier this year -- another multi-billion dollar field predicted by industry leaders. In addition, InWith is still aiming to make an acquisition of EPGL IP and shareholders as soon as possible unless another entity beats them to it. EPGL and InWith Corp. announced today that they will partner to build the "InLens 1.0" brand of electronic augmented, mobile contact lenses. The "InLens" line is planned to include augmented reality, autofocus and more electronic contact lens applications tied to mobile phone applications. In 2016, EPGL received the US Patent on the "Elastic Circuit" which is an essential element for molding and mass production of soft electronic contact lenses. Electronically enhanced contact lenses are the ultimate platform for augmented vision ($150 billion estimated market), advanced forms of vision correction, diagnostics and drug delivery. "InLenses" will be built to be compatible with both Apple iOS and Google Android Operating systems. The mobile network will open the door to perhaps hundreds of vision based display applications in the future. EPGL has multiple ophthalmic patents pending in this field. Already, Johnson & Johnson Vision Care, Inc. has acquired first rights to purchase the working products that are built from EPGL technologies. Today's announcement marks the beginning of the next phase for building and commercialization. "With our progress, we have the unprecedented opportunity to become the market leader in this multi-billion dollar electronic /ophthalmic field. We now own the IP that giants have been seeking and we have the know-how to back up what we have planned," said Michael Hayes, President of EPGL. Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Novartis CEO Joseph Jimenez has told the Financial Times that the market for an "Autofocus" contact lens could be worth, "anywhere between $10 billion and $50 billion in the next ten years." The Financial Times went on to say; "While Google's efforts building a smart lens with a built-in wireless chip and glucose sensor have grabbed most headlines so far, the really juicy opportunity is in corrective eyewear. If the company can build a contact lens that offers its wearer 'autofocus' powers similar to those found in digital cameras for bringing scenes into tight focus, it can address a range of eye ailments and failings with a single solution, rather than requiring the kinds of fixed prescriptions that we use now, and that are often compromises rather than perfect solutions." For the first time, EPGL is revealing specifically that it has developed technology for an "Autofocus" contact lens with CooperVision, Inc. "We know we are ahead of Google and Novartis because Novartis executives reached out to us in 2013. We declined because we were already ahead and inventing new electronics for contact lenses at that point," said David Markus, Ph.D. "We posted proof of this request in 2014," Markus added. "We also posted an example of a recent patent filing so that investors could verify that too." "The investment community has been asking for specifics on what we possess and here you go," said Michael Hayes, CEO of EPGL. "You have the CEO of a $280 billion company publicly stating that 'Autofocus' contact lens technology is worth $10 to $50 billion annually. EPGL owns key 'Autofocus' technology that is likely to beat Novartis and Google to market. Given that fact, is our present 5 cent per share stock price a bargain right now? Yes I believe it is. Will it remain at this level as the clock ticks at the USPTO? No I do not believe so," added Hayes. "With this news EPGL is going to be discovered by more investors and I believe we may surpass .88 cents or even $1.00+ as our patents pending progress. Current EPGL investors are in at just the right time in my opinion." Since Announcing Settlement with CooperVision, Inc., at the beginning of 2016, in which EPGL gained full ownership of its pending patents, EPGL management has been receiving inquiries from major industry titans. The Company is now negotiating its first new relationships since that time while continuing to progress its pending patents. To that end, EPGL has filed the latest in a series of patents pending in the hot new field of smart contact lens technology. The latest filing is for an optic display mechanism within the contact lens which could lay a new foundation for augmented reality (AR) in the field of vision. The original US provisional version of this patent was filed over a year ago and the new PCT filing is not yet public. "The major difference with EPGL's technology and the competition thus far is that we are the only company to publicly show our electronic circuitry material in a photo; which has been proven to integrate distortion free into real silicone hydrogel contact lenses," said Michael Hayes, President of EPGL. "That's a big deal considering our competition is Google, Facebook and Samsung to name a few. EPGL is a major player given some of our pending patents," Hayes added. What is the big deal about smart contact lens technology you ask? The vision revolution underway with such virtual reality entries as Oculus by Facebook and Hololens by Microsoft is just in its infancy, estimated at $150 billion. The market for augmented reality or "AR" is equally large. That is where contact lenses come in. The holy grail of the industry is to put AR into the smallest, most discrete wearable you can find. Many industry leading CEO's estimate that most of what you can do with your smartphone today will be integrated into or onto your body in the future. Data display and electronic vision enhancement is going to be a major part of peoples' lives going into the future. Several of EPGL's patents pending have become public in recent weeks resulting in new interest from major companies. In addition to several patents pending, EPGL recently published a photo on www.epglmed.com of its electronic circuitry platform developed and bench tested at world-class contact lens manufacturing facilities. The photo is the only known picture made public to date of electronic circuitry that has been proven to integrate successfully into real-world silicone hydrogel contact lenses. When EPGL was developing the technology with CooperVision, Inc., the challenge was to create electronic circuitry substrate that could withstand the rigors of the state of the art contact lens manufacturing process and come out the other end intact and without distortion. EPGL's design does not require expensive layering techniques or re-tooling of the current mold process during manufacturing, thus making it a very attractive and less costly solution. EP Global Communications, Inc. and EPGL Medical (the Company), (OTC-PINK: EPGL) announced today that Company engineers have invented the world's first self powered, self contained, power source for contact lenses. The power supply comes from within the lenses and is self perpetuating day or night. "Using cutting edge technology, EPGL has invented a self perpetuating power source for lenses which does not require external energy such as RF," said David Markus PhD. "The market for contact lenses as information data display devices is just beginning and will be a natural extension of new wearable data devices such as Google Glass." EPGL intends to license the new technology to companies who are developing data display for contact lenses. Researchers are now designing applications for use in contact lenses for both health care and consumer needs. One use of powered contact lenses being investigated is for displaying data in real-time to the lenses wearer about medical data such as their blood sugar level, oxygen level, heart rate, EKG and many other possible medical applications. Powered contact lenses are also being looked into as delivery devices for drugs and other therapeutic applications. In the consumer electronics market, powered contact lenses have promise to display data from the Internet directly into the wearer's field of vision real-time. "Imagine being able to have telescopic vision on demand or microscopic vision. The applications for what people could want to have displayed in their vision at the blink of an eye are virtually endless," said Michael Hayes, President of EPGL Medical. "We intend to license the new power technology for those applications because the future market is obviously significant in size and scope." Congratulations if you read everything. I basically want to say this. I. love. sorority. girls. Go EPGL! The aforementioned patents pending join other EPGL technologies such as its piezoelectric sensor in a contact lens which uses the vibration of the Ciliary muscles in the eye to actuate autofocus capabilities, the technique for creating pre-defined spaces within a contact lens for mechanisms and reservoirs, energy harvesting of the eye movement and an additional non-public patent as yet for changing the focus of a contact lens upon demand by the human eye. In a joint statement, EPGL announces that it has received its third consecutive US Patent allowance in the field of ophthalmic technologies while start-up partner InWith Corp. announces it will make a bid to buyout EPGL. For EPGL, the allowed US Patent titled "Piezoelectric Sensor for Vision Correction" (U.S. 14/622,814), protects the sensing of the vibration of the ciliary muscle within the human eye, to trigger a self-focus mechanism within a soft contact lenses. EPGL's IP counsel was recently notified of the Allowance by the United States Patent and Trademark Office. InWith Corp., a start-up company with plans to make new "body technologies" from wearable devices to implantable devices tied to a mobile wireless network, announced that it is seeking as much as $500 million in private funding. InWith Corp. is a private company with 100 million authorized shares. InWith Corp. and EPGL previously announced a partnership to build EPGL's patented ophthalmic technologies. Several EPGL shareholders have requested and will receive a gift of Inwith Corp. equity. As a result, InWith Corp. will have private shareholders from all over the world. The Company has announced that Dr. Scott Peterson will be its Vice President. Dr. Peterson has been in practice for over 33 years and specializes in Glaucoma treatment and contact lenses. The management team of InWith Corp. will be fully announced by end of February 2017. InWith Corp. will make a bid to buyout EP Global Communications, Inc. (EPGL) if EPGL shareholders allow the full offer to be presented by InWith Corp. via a Proxy Vote. The offer will involve a choice for EPGL's retail shareholders to be bought out in a cash price of up to 9.8 cents per share, or to receive approximately 125% of their current EPGL equity by percentage (total along with gifted shares) converted to InWith Corp. equity. The choice would be offered as "one or the other" to EPGL shareholders and they could make their choice individually from other shareholders. In any event, EPGL shareholders who formally requested the InWith Corp. gift equity offer, will receive that gift equity regardless if a full buyout is finalized. EPGL will put the InWith Corp. detailed proposal before its shareholders in a Proxy Vote. The Company notes that other entities who hold first rights to purchase EPGL technologies, will continue to enjoy those rights through to the building of the products, regardless of any completed buyout. EP Global Communications, Inc. (OTC: EPGL) In a first for EPGL since acquiring 100% of its ophthalmic IP portfolio, one of the world's leading multi-billion-dollar public companies, in a brand-new relationship for EPGL, has made EPGL technology and its patented Elastic Circuit technology as the choice for a closely guarded and proprietary development of a new contact lens prototype to undergo FDA testing as early as next year. This goes beyond a right of first negotiation to now having EPGL technology at the center of a commercial project that addresses a multi-billion-dollar market in the field. "We are on target with our strategy and the proof is that major companies are now choosing EPGL tech for actual market commercialization, not just first rights. Just as the number of our patents has grown, the number of corporate suitors for our technology will grow exponentially, I predict. Smart investors should take positions now if they believe we have growth potential for the next phase of EPGL and InWith, which starts today," said Michael Hayes. "As we promised, our patents are getting granted and becoming more and more valuable to other major entities as they begin to pursue projects for the next generation of vision care and augmentation. The next phase has started and savvy investors can participate." In addition to the brand-new developments announced here today, EPGL and InWith (www.inwithcorp.com) plan to announce major venture capital partners between now and the holiday season. As a new start-up, InWith will license EPGL technology and is aggressively pursuing the InLens / Omega autofocus projects announced earlier this year -- another multi-billion dollar field predicted by industry leaders. In addition, InWith is still aiming to make an acquisition of EPGL IP and shareholders as soon as possible unless another entity beats them to it. EPGL and InWith Corp. announced today that they will partner to build the "InLens 1.0" brand of electronic augmented, mobile contact lenses. The "InLens" line is planned to include augmented reality, autofocus and more electronic contact lens applications tied to mobile phone applications. In 2016, EPGL received the US Patent on the "Elastic Circuit" which is an essential element for molding and mass production of soft electronic contact lenses. Electronically enhanced contact lenses are the ultimate platform for augmented vision ($150 billion estimated market), advanced forms of vision correction, diagnostics and drug delivery. "InLenses" will be built to be compatible with both Apple iOS and Google Android Operating systems. The mobile network will open the door to perhaps hundreds of vision based display applications in the future. EPGL has multiple ophthalmic patents pending in this field. Already, Johnson & Johnson Vision Care, Inc. has acquired first rights to purchase the working products that are built from EPGL technologies. Today's announcement marks the beginning of the next phase for building and commercialization. "With our progress, we have the unprecedented opportunity to become the market leader in this multi-billion dollar electronic /ophthalmic field. We now own the IP that giants have been seeking and we have the know-how to back up what we have planned," said Michael Hayes, President of EPGL. Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Novartis CEO Joseph Jimenez has told the Financial Times that the market for an "Autofocus" contact lens could be worth, "anywhere between $10 billion and $50 billion in the next ten years." The Financial Times went on to say; "While Google's efforts building a smart lens with a built-in wireless chip and glucose sensor have grabbed most headlines so far, the really juicy opportunity is in corrective eyewear. If the company can build a contact lens that offers its wearer 'autofocus' powers similar to those found in digital cameras for bringing scenes into tight focus, it can address a range of eye ailments and failings with a single solution, rather than requiring the kinds of fixed prescriptions that we use now, and that are often compromises rather than perfect solutions." For the first time, EPGL is revealing specifically that it has developed technology for an "Autofocus" contact lens with CooperVision, Inc. "We know we are ahead of Google and Novartis because Novartis executives reached out to us in 2013. We declined because we were already ahead and inventing new electronics for contact lenses at that point," said David Markus, Ph.D. "We posted proof of this request in 2014," Markus added. "We also posted an example of a recent patent filing so that investors could verify that too." "The investment community has been asking for specifics on what we possess and here you go," said Michael Hayes, CEO of EPGL. "You have the CEO of a $280 billion company publicly stating that 'Autofocus' contact lens technology is worth $10 to $50 billion annually. EPGL owns key 'Autofocus' technology that is likely to beat Novartis and Google to market. Given that fact, is our present 5 cent per share stock price a bargain right now? Yes I believe it is. Will it remain at this level as the clock ticks at the USPTO? No I do not believe so," added Hayes. "With this news EPGL is going to be discovered by more investors and I believe we may surpass .88 cents or even $1.00+ as our patents pending progress. Current EPGL investors are in at just the right time in my opinion." Since Announcing Settlement with CooperVision, Inc., at the beginning of 2016, in which EPGL gained full ownership of its pending patents, EPGL management has been receiving inquiries from major industry titans. The Company is now negotiating its first new relationships since that time while continuing to progress its pending patents. To that end, EPGL has filed the latest in a series of patents pending in the hot new field of smart contact lens technology. The latest filing is for an optic display mechanism within the contact lens which could lay a new foundation for augmented reality (AR) in the field of vision. The original US provisional version of this patent was filed over a year ago and the new PCT filing is not yet public. "The major difference with EPGL's technology and the competition thus far is that we are the only company to publicly show our electronic circuitry material in a photo; which has been proven to integrate distortion free into real silicone hydrogel contact lenses," said Michael Hayes, President of EPGL. "That's a big deal considering our competition is Google, Facebook and Samsung to name a few. EPGL is a major player given some of our pending patents," Hayes added. What is the big deal about smart contact lens technology you ask? The vision revolution underway with such virtual reality entries as Oculus by Facebook and Hololens by Microsoft is just in its infancy, estimated at $150 billion. The market for augmented reality or "AR" is equally large. That is where contact lenses come in. The holy grail of the industry is to put AR into the smallest, most discrete wearable you can find. Many industry leading CEO's estimate that most of what you can do with your smartphone today will be integrated into or onto your body in the future. Data display and electronic vision enhancement is going to be a major part of peoples' lives going into the future. Several of EPGL's patents pending have become public in recent weeks resulting in new interest from major companies. In addition to several patents pending, EPGL recently published a photo on www.epglmed.com of its electronic circuitry platform developed and bench tested at world-class contact lens manufacturing facilities. The photo is the only known picture made public to date of electronic circuitry that has been proven to integrate successfully into real-world silicone hydrogel contact lenses. When EPGL was developing the technology with CooperVision, Inc., the challenge was to create electronic circuitry substrate that could withstand the rigors of the state of the art contact lens manufacturing process and come out the other end intact and without distortion. EPGL's design does not require expensive layering techniques or re-tooling of the current mold process during manufacturing, thus making it a very attractive and less costly solution. EP Global Communications, Inc. and EPGL Medical (the Company), (OTC-PINK: EPGL) announced today that Company engineers have invented the world's first self powered, self contained, power source for contact lenses. The power supply comes from within the lenses and is self perpetuating day or night. "Using cutting edge technology, EPGL has invented a self perpetuating power source for lenses which does not require external energy such as RF," said David Markus PhD. "The market for contact lenses as information data display devices is just beginning and will be a natural extension of new wearable data devices such as Google Glass." EPGL intends to license the new technology to companies who are developing data display for contact lenses. Researchers are now designing applications for use in contact lenses for both health care and consumer needs. One use of powered contact lenses being investigated is for displaying data in real-time to the lenses wearer about medical data such as their blood sugar level, oxygen level, heart rate, EKG and many other possible medical applications. Powered contact lenses are also being looked into as delivery devices for drugs and other therapeutic applications. In the consumer electronics market, powered contact lenses have promise to display data from the Internet directly into the wearer's field of vision real-time. "Imagine being able to have telescopic vision on demand or microscopic vision. The applications for what people could want to have displayed in their vision at the blink of an eye are virtually endless," said Michael Hayes, President of EPGL Medical. "We intend to license the new power technology for those applications because the future market is obviously significant in size and scope." Congratulations if you read everything. I basically want to say this. I. love. sorority. girls. Go EPGL! The aforementioned patents pending join other EPGL technologies such as its piezoelectric sensor in a contact lens which uses the vibration of the Ciliary muscles in the eye to actuate autofocus capabilities, the technique for creating pre-defined spaces within a contact lens for mechanisms and reservoirs, energy harvesting of the eye movement and an additional non-public patent as yet for changing the focus of a contact lens upon demand by the human eye. In a joint statement, EPGL announces that it has received its third consecutive US Patent allowance in the field of ophthalmic technologies while start-up partner InWith Corp. announces it will make a bid to buyout EPGL. For EPGL, the allowed US Patent titled "Piezoelectric Sensor for Vision Correction" (U.S. 14/622,814), protects the sensing of the vibration of the ciliary muscle within the human eye, to trigger a self-focus mechanism within a soft contact lenses. EPGL's IP counsel was recently notified of the Allowance by the United States Patent and Trademark Office. InWith Corp., a start-up company with plans to make new "body technologies" from wearable devices to implantable devices tied to a mobile wireless network, announced that it is seeking as much as $500 million in private funding. InWith Corp. is a private company with 100 million authorized shares. InWith Corp. and EPGL previously announced a partnership to build EPGL's patented ophthalmic technologies. Several EPGL shareholders have requested and will receive a gift of Inwith Corp. equity. As a result, InWith Corp. will have private shareholders from all over the world. The Company has announced that Dr. Scott Peterson will be its Vice President. Dr. Peterson has been in practice for over 33 years and specializes in Glaucoma treatment and contact lenses. The management team of InWith Corp. will be fully announced by end of February 2017. InWith Corp. will make a bid to buyout EP Global Communications, Inc. (EPGL) if EPGL shareholders allow the full offer to be presented by InWith Corp. via a Proxy Vote. The offer will involve a choice for EPGL's retail shareholders to be bought out in a cash price of up to 9.8 cents per share, or to receive approximately 125% of their current EPGL equity by percentage (total along with gifted shares) converted to InWith Corp. equity. The choice would be offered as "one or the other" to EPGL shareholders and they could make their choice individually from other shareholders. In any event, EPGL shareholders who formally requested the InWith Corp. gift equity offer, will receive that gift equity regardless if a full buyout is finalized. EPGL will put the InWith Corp. detailed proposal before its shareholders in a Proxy Vote. The Company notes that other entities who hold first rights to purchase EPGL technologies, will continue to enjoy those rights through to the building of the products, regardless of any completed buyout. EP Global Communications, Inc. (OTC: EPGL) In a first for EPGL since acquiring 100% of its ophthalmic IP portfolio, one of the world's leading multi-billion-dollar public companies, in a brand-new relationship for EPGL, has made EPGL technology and its patented Elastic Circuit technology as the choice for a closely guarded and proprietary development of a new contact lens prototype to undergo FDA testing as early as next year. This goes beyond a right of first negotiation to now having EPGL technology at the center of a commercial project that addresses a multi-billion-dollar market in the field. "We are on target with our strategy and the proof is that major companies are now choosing EPGL tech for actual market commercialization, not just first rights. Just as the number of our patents has grown, the number of corporate suitors for our technology will grow exponentially, I predict. Smart investors should take positions now if they believe we have growth potential for the next phase of EPGL and InWith, which starts today," said Michael Hayes. "As we promised, our patents are getting granted and becoming more and more valuable to other major entities as they begin to pursue projects for the next generation of vision care and augmentation. The next phase has started and savvy investors can participate." In addition to the brand-new developments announced here today, EPGL and InWith (www.inwithcorp.com) plan to announce major venture capital partners between now and the holiday season. As a new start-up, InWith will license EPGL technology and is aggressively pursuing the InLens / Omega autofocus projects announced earlier this year -- another multi-billion dollar field predicted by industry leaders. In addition, InWith is still aiming to make an acquisition of EPGL IP and shareholders as soon as possible unless another entity beats them to it. EPGL and InWith Corp. announced today that they will partner to build the "InLens 1.0" brand of electronic augmented, mobile contact lenses. The "InLens" line is planned to include augmented reality, autofocus and more electronic contact lens applications tied to mobile phone applications. In 2016, EPGL received the US Patent on the "Elastic Circuit" which is an essential element for molding and mass production of soft electronic contact lenses. Electronically enhanced contact lenses are the ultimate platform for augmented vision ($150 billion estimated market), advanced forms of vision correction, diagnostics and drug delivery. "InLenses" will be built to be compatible with both Apple iOS and Google Android Operating systems. The mobile network will open the door to perhaps hundreds of vision based display applications in the future. EPGL has multiple ophthalmic patents pending in this field. Already, Johnson & Johnson Vision Care, Inc. has acquired first rights to purchase the working products that are built from EPGL technologies. Today's announcement marks the beginning of the next phase for building and commercialization. "With our progress, we have the unprecedented opportunity to become the market leader in this multi-billion dollar electronic /ophthalmic field. We now own the IP that giants have been seeking and we have the know-how to back up what we have planned," said Michael Hayes, President of EPGL. Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Novartis CEO Joseph Jimenez has told the Financial Times that the market for an "Autofocus" contact lens could be worth, "anywhere between $10 billion and $50 billion in the next ten years." The Financial Times went on to say; "While Google's efforts building a smart lens with a built-in wireless chip and glucose sensor have grabbed most headlines so far, the really juicy opportunity is in corrective eyewear. If the company can build a contact lens that offers its wearer 'autofocus' powers similar to those found in digital cameras for bringing scenes into tight focus, it can address a range of eye ailments and failings with a single solution, rather than requiring the kinds of fixed prescriptions that we use now, and that are often compromises rather than perfect solutions." For the first time, EPGL is revealing specifically that it has developed technology for an "Autofocus" contact lens with CooperVision, Inc. "We know we are ahead of Google and Novartis because Novartis executives reached out to us in 2013. We declined because we were already ahead and inventing new electronics for contact lenses at that point," said David Markus, Ph.D. "We posted proof of this request in 2014," Markus added. "We also posted an example of a recent patent filing so that investors could verify that too." "The investment community has been asking for specifics on what we possess and here you go," said Michael Hayes, CEO of EPGL. "You have the CEO of a $280 billion company publicly stating that 'Autofocus' contact lens technology is worth $10 to $50 billion annually. EPGL owns key 'Autofocus' technology that is likely to beat Novartis and Google to market. Given that fact, is our present 5 cent per share stock price a bargain right now? Yes I believe it is. Will it remain at this level as the clock ticks at the USPTO? No I do not believe so," added Hayes. "With this news EPGL is going to be discovered by more investors and I believe we may surpass .88 cents or even $1.00+ as our patents pending progress. Current EPGL investors are in at just the right time in my opinion." Since Announcing Settlement with CooperVision, Inc., at the beginning of 2016, in which EPGL gained full ownership of its pending patents, EPGL management has been receiving inquiries from major industry titans. The Company is now negotiating its first new relationships since that time while continuing to progress its pending patents. To that end, EPGL has filed the latest in a series of patents pending in the hot new field of smart contact lens technology. The latest filing is for an optic display mechanism within the contact lens which could lay a new foundation for augmented reality (AR) in the field of vision. The original US provisional version of this patent was filed over a year ago and the new PCT filing is not yet public. "The major difference with EPGL's technology and the competition thus far is that we are the only company to publicly show our electronic circuitry material in a photo; which has been proven to integrate distortion free into real silicone hydrogel contact lenses," said Michael Hayes, President of EPGL. "That's a big deal considering our competition is Google, Facebook and Samsung to name a few. EPGL is a major player given some of our pending patents," Hayes added. What is the big deal about smart contact lens technology you ask? The vision revolution underway with such virtual reality entries as Oculus by Facebook and Hololens by Microsoft is just in its infancy, estimated at $150 billion. The market for augmented reality or "AR" is equally large. That is where contact lenses come in. The holy grail of the industry is to put AR into the smallest, most discrete wearable you can find. Many industry leading CEO's estimate that most of what you can do with your smartphone today will be integrated into or onto your body in the future. Data display and electronic vision enhancement is going to be a major part of peoples' lives going into the future. Several of EPGL's patents pending have become public in recent weeks resulting in new interest from major companies. In addition to several patents pending, EPGL recently published a photo on www.epglmed.com of its electronic circuitry platform developed and bench tested at world-class contact lens manufacturing facilities. The photo is the only known picture made public to date of electronic circuitry that has been proven to integrate successfully into real-world silicone hydrogel contact lenses. When EPGL was developing the technology with CooperVision, Inc., the challenge was to create electronic circuitry substrate that could withstand the rigors of the state of the art contact lens manufacturing process and come out the other end intact and without distortion. EPGL's design does not require expensive layering techniques or re-tooling of the current mold process during manufacturing, thus making it a very attractive and less costly solution. EP Global Communications, Inc. and EPGL Medical (the Company), (OTC-PINK: EPGL) announced today that Company engineers have invented the world's first self powered, self contained, power source for contact lenses. The power supply comes from within the lenses and is self perpetuating day or night. "Using cutting edge technology, EPGL has invented a self perpetuating power source for lenses which does not require external energy such as RF," said David Markus PhD. "The market for contact lenses as information data display devices is just beginning and will be a natural extension of new wearable data devices such as Google Glass." EPGL intends to license the new technology to companies who are developing data display for contact lenses. Researchers are now designing applications for use in contact lenses for both health care and consumer needs. One use of powered contact lenses being investigated is for displaying data in real-time to the lenses wearer about medical data such as their blood sugar level, oxygen level, heart rate, EKG and many other possible medical applications. Powered contact lenses are also being looked into as delivery devices for drugs and other therapeutic applications. In the consumer electronics market, powered contact lenses have promise to display data from the Internet directly into the wearer's field of vision real-time. "Imagine being able to have telescopic vision on demand or microscopic vision. The applications for what people could want to have displayed in their vision at the blink of an eye are virtually endless," said Michael Hayes, President of EPGL Medical. "We intend to license the new power technology for those applications because the future market is obviously significant in size and scope." Congratulations if you read everything. I basically want to say this. I. love. sorority. girls. Go EPGL! The aforementioned patents pending join other EPGL technologies such as its piezoelectric sensor in a contact lens which uses the vibration of the Ciliary muscles in the eye to actuate autofocus capabilities, the technique for creating pre-defined spaces within a contact lens for mechanisms and reservoirs, energy harvesting of the eye movement and an additional non-public patent as yet for changing the focus of a contact lens upon demand by the human eye.